Rochester, Minn.-based Mayo Clinic led the study testing the product, DermaSensor, among more than 1,000 patients, according to a news release from the device’s maker. In the study, the device had a 96% sensitivity across 224 skin cancers.
The technology is indicated to further evaluate suspicious-looking lesions rather than a screening tool, according to the FDA. It can help spot melanoma and assess moles for basal cell carcinoma and squamous cell carcinoma.
“Achieving this medical milestone is a testament to the 12 years and tens of millions of dollars our company has invested in research and development to bring this powerful technology to market,” Maurice Ferre, MD, co-founder and chair of DermaSensor, said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
